111 related articles for article (PubMed ID: 26608168)
21. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
22. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.
Mossadegh N; Gissmann L; Müller M; Zentgraf H; Alonso A; Tomakidi P
Virology; 2004 Aug; 326(1):57-66. PubMed ID: 15262495
[TBL] [Abstract][Full Text] [Related]
23. Enhanced expression of soluble human papillomavirus L1 through coexpression of molecular chaperonin in Escherichia coli.
Pan D; Zha X; Yu X; Wu Y
Protein Expr Purif; 2016 Apr; 120():92-8. PubMed ID: 26732286
[TBL] [Abstract][Full Text] [Related]
24. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.
Chen XS; Casini G; Harrison SC; Garcea RL
J Mol Biol; 2001 Mar; 307(1):173-82. PubMed ID: 11243812
[TBL] [Abstract][Full Text] [Related]
25. Cloning and Expression of L1 Protein Human Papillomavirus Type 31 Isolated from Iranian Patients in Escherichia coli.
Hajmohammadi S; Rassi H
Monoclon Antib Immunodiagn Immunother; 2016 Aug; 35(4):181-5. PubMed ID: 27244269
[TBL] [Abstract][Full Text] [Related]
26. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
Schädlich L; Senger T; Kirschning CJ; Müller M; Gissmann L
Vaccine; 2009 Mar; 27(10):1511-22. PubMed ID: 19174177
[TBL] [Abstract][Full Text] [Related]
27. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
[TBL] [Abstract][Full Text] [Related]
28. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography.
Baek JO; Seo JW; Kim IH; Kim CH
Protein Expr Purif; 2011 Feb; 75(2):211-7. PubMed ID: 20716445
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
30. Efficient expression and purification of porcine circovirus type 2 virus-like particles in Escherichia coli.
Wu PC; Chen TY; Chi JN; Chien MS; Huang C
J Biotechnol; 2016 Feb; 220():78-85. PubMed ID: 26795354
[TBL] [Abstract][Full Text] [Related]
31. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.
Kim SN; Jeong HS; Park SN; Kim HJ
J Virol Methods; 2007 Jan; 139(1):24-30. PubMed ID: 17034867
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles.
Heino P; Dillner J; Schwartz S
Virology; 1995 Dec; 214(2):349-59. PubMed ID: 8553535
[TBL] [Abstract][Full Text] [Related]
33. Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae.
Park MA; Kim HJ; Kim HJ
Protein Expr Purif; 2008 May; 59(1):175-81. PubMed ID: 18343683
[TBL] [Abstract][Full Text] [Related]
34. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
[TBL] [Abstract][Full Text] [Related]
35. [Mutations of human papillomavirus (HPV) 16 type L1 genes from cervical carcinoma biopsies in southern Xinjiang Uygur women].
Ma ZH; Zhang FC; Mei XD; Ma CL; Liu KJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):987-91. PubMed ID: 15312531
[TBL] [Abstract][Full Text] [Related]
36. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
Pineo CB; Hitzeroth II; Rybicki EP
Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
[TBL] [Abstract][Full Text] [Related]
37. Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles.
Patel MC; Patkar KK; Basu A; Mohandas KM; Mukhopadhyaya R
Indian J Med Res; 2009 Sep; 130(3):213-8. PubMed ID: 19901429
[TBL] [Abstract][Full Text] [Related]
38. Expression of human papillomavirus type 16 L1 in baculovirus expression systems: a case study.
Jin Z; Lusheng S; Yili W
Methods Mol Biol; 2005; 308():77-86. PubMed ID: 16082027
[No Abstract] [Full Text] [Related]
39. Production of L1 protein from different types of HPV in Pichia pastoris using an integrative vector.
Coimbra EC; Gomes FB; Campos JF; D'arc M; Carvalho JC; Mariz FC; Jesus AL; Stocco RC; Beçak W; Freitas AC
Braz J Med Biol Res; 2011 Dec; 44(12):1209-14. PubMed ID: 22030867
[TBL] [Abstract][Full Text] [Related]
40. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.
Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y
Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
